Retatrutide and 5-Amino-1MQ are two compounds generating considerable interest in metabolic health and weight management circles, yet neither holds a marketing authorisation in the UK. Retatrutide is an investigational triple incretin receptor agonist under clinical development by Eli Lilly, whilst 5-Amino-1MQ is a research chemical targeting the NNMT enzyme. Both are being discussed — and in some cases sold — online, raising serious patient safety concerns. This article examines what each compound is, how they work, the current evidence base, and the significant regulatory and safety considerations UK patients and clinicians need to understand.

What Are Retatrutide and 5-Amino-1MQ?

Retatrutide is an unlicensed investigational triple incretin receptor agonist by Eli Lilly; 5-Amino-1MQ is an unapproved research chemical that inhibits the NNMT enzyme, with neither compound holding UK marketing authorisation.

Retatrutide is an investigational peptide drug currently under clinical development by Eli Lilly. It is classified as a triple incretin receptor agonist, meaning it simultaneously targets three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This multi-receptor approach distinguishes it from existing licensed medicines such as semaglutide (Ozempic, Wegovy) or tirzepatide — licensed in the UK as Mounjaro for type 2 diabetes and as Zepbound for obesity — which act on fewer receptor pathways.^[2][11] As of 2026, retatrutide has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and it remains an experimental compound available only within authorised clinical trial settings. Patients and clinicians should verify the current status with the MHRA and EMA, as the regulatory position may change.

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule compound that has attracted interest in metabolic research. It acts as a selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme expressed in multiple tissues — including adipose tissue and the liver — that plays a role in cellular energy metabolism and fat storage. Research into 5-Amino-1MQ has been conducted primarily in preclinical (animal and cellular) models, and it has not been approved by the MHRA, NICE, or any major regulatory authority for human therapeutic use. Despite this, it is increasingly being marketed online — often alongside other metabolic compounds — raising significant patient safety concerns. The MHRA has issued broader warnings about the risks of purchasing unlicensed medicines and research chemicals online. Neither compound should be considered a licensed medicine in the UK, and both require careful scrutiny before any consideration of use.

How Each Compound Works in the Body

Retatrutide activates GLP-1, GIP, and glucagon receptors to reduce appetite, increase energy expenditure, and improve insulin secretion; 5-Amino-1MQ inhibits NNMT to theoretically raise NAD+ levels, though human evidence is absent.

Retatrutide's mechanism of action centres on its simultaneous activation of GLP-1, GIP, and glucagon receptors. GLP-1 receptor agonism promotes insulin secretion in a glucose-dependent manner, reduces appetite, and slows gastric emptying. GIP receptor agonism further enhances insulin release and may improve fat metabolism. Glucagon receptor agonism increases energy expenditure and promotes hepatic fatty acid oxidation, which may contribute to reductions in liver fat content. It is important to note that the glucose-raising effect of glucagon receptor activation is largely counterbalanced by the GLP-1 and GIP components. Together, these actions are thought to produce more pronounced weight loss and metabolic improvements than dual or single receptor agonists. Phase 2 clinical trial data published in the New England Journal of Medicine (Jastreboff et al., 2023) demonstrated mean body weight reductions of up to approximately 24% over 48 weeks in adults with obesity — a notable finding, though long-term durability data and head-to-head comparisons with other treatments are not yet available.

GLP-1 and GIP receptor agonists have a low intrinsic risk of causing hypoglycaemia when used alone, because their insulin-stimulating effects are glucose-dependent.^[8][9] The risk of low blood sugar increases meaningfully only when these agents are combined with insulin or sulfonylureas.

5-Amino-1MQ works through a different and more upstream metabolic pathway. NNMT is an enzyme expressed in adipose tissue, the liver, and other tissues. When NNMT is overactive, it consumes S-adenosylmethionine (SAM) and reduces levels of nicotinamide adenine dinucleotide (NAD+), a critical coenzyme involved in cellular energy production. Based on preclinical (animal and cellular) data only, inhibition of NNMT by 5-Amino-1MQ is theorised to:

• Raise intracellular NAD+ levels

• Activate SIRT1 and other sirtuins (proteins linked to metabolic regulation)

• Reduce fat cell (adipocyte) size and proliferation

• Improve insulin sensitivity

These effects have been demonstrated in mouse models (Neelakantan et al., 2019), but robust human clinical trial data are currently absent. All mechanistic claims for 5-Amino-1MQ in humans remain theoretical, and it is premature to draw firm conclusions about efficacy or safety in people.

Potential Benefits and Current Research Evidence

Phase 2 trial data support retatrutide's efficacy for weight reduction in obesity, but 5-Amino-1MQ has no published human clinical trials and its benefits in people remain unproven.

The research interest in retatrutide is substantial and grounded in peer-reviewed clinical data. Phase 2 trials (Jastreboff et al., NEJM, 2023) have shown it to be highly effective for weight reduction in adults with obesity. Some participants achieved weight loss of approximately 24% of body weight at 48 weeks — approaching levels reported with some bariatric surgical procedures, though no direct head-to-head comparisons have been conducted and long-term durability beyond the trial period remains unknown. Beyond weight loss, early exploratory data suggest potential benefits including:

• Reductions in HbA1c (a marker of blood sugar control) in people with type 2 diabetes

• Improvements in lipid profiles (cholesterol and triglycerides)

• Reductions in liver fat, which may be relevant for metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), though these findings are preliminary

• Possible cardiovascular benefits; however, dedicated cardiovascular outcome trial (CVOT) data have not yet been published, and cardiovascular benefit has not been demonstrated

Phase 3 trials are ongoing. Until these are completed and regulatory approval is granted, retatrutide cannot be prescribed or legally supplied in the UK.

For 5-Amino-1MQ, the evidence base is considerably more limited. Preclinical studies in rodents have demonstrated reductions in fat mass, improved insulin sensitivity, and increased metabolic rate without significant changes to food intake (Neelakantan et al., 2019). However, no peer-reviewed human clinical trials have been published to date. The leap from animal model findings to confirmed human benefit is significant, and many compounds that show promise in preclinical research do not translate successfully to human medicine. The current evidence is therefore insufficient to support therapeutic claims for 5-Amino-1MQ in people.

Safety Concerns, Risks, and Regulatory Status in the UK

Neither compound is licensed in the UK; retatrutide carries GLP-1 class risks including nausea and pancreatitis, whilst 5-Amino-1MQ has no established human safety profile and is sold online without quality verification.

From a regulatory standpoint, neither retatrutide nor 5-Amino-1MQ holds a marketing authorisation in the UK. Retatrutide is an investigational medicinal product (IMP) accessible only through authorised clinical trials. Purchasing or supplying it outside of this framework is not legally sanctioned and carries significant risks, including exposure to counterfeit or contaminated products.

5-Amino-1MQ occupies a particularly ambiguous regulatory space. It is not classified as a controlled substance under the Misuse of Drugs Act 1971, but it is also not approved as a medicine or food supplement. Products sold online may not meet pharmaceutical-grade manufacturing standards, and their purity, dosage accuracy, and safety profiles are unverified. The MHRA has issued guidance on the risks of purchasing unlicensed medicines and research chemicals online, and patients are strongly advised to consult this guidance before considering any such purchase.

Known and theoretical safety concerns include:

• Retatrutide (and the GLP-1 receptor agonist class): Nausea, vomiting, diarrhoea, and reduced appetite are the most commonly reported side effects. Prolonged vomiting or diarrhoea can lead to dehydration and, in some cases, acute kidney injury (AKI). Gallbladder disease, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis), has been reported with GLP-1 receptor agonists as a class.^[11][12] There is a potential risk of pancreatitis. Rodent studies have identified thyroid C-cell changes; the clinical relevance of this finding in humans is unknown, and in UK and EU prescribing information this is noted as a precaution rather than a formal contraindication — but individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) should discuss this with their doctor.

• 5-Amino-1MQ: No established human safety profile exists; long-term effects on NAD+ metabolism, liver function, and cardiovascular health are unknown; dosing from unregulated online sources is unverified.

Patients with pre-existing conditions — including cardiovascular disease, liver disease, thyroid disorders, kidney disease, or gallbladder disease — face particular uncertainty. Self-administration of either compound without medical supervision represents a significant and unquantified health risk.

If you suspect you have experienced a side effect from any medicine or research chemical, you can report it to the MHRA via the Yellow Card Scheme (yellowcard.mhra.gov.uk). This applies to licensed and unlicensed products alike and helps the MHRA monitor the safety of medicines used in the UK.

Known and Theoretical Interactions Between These Compounds

No human studies exist on combining retatrutide and 5-Amino-1MQ; theoretical risks include increased hypoglycaemia, unpredictable cardiovascular effects, and compounded uncertainty from two incompletely characterised compounds.

There are currently no published clinical studies examining the combined use of retatrutide and 5-Amino-1MQ in humans. Any discussion of interactions between these two compounds is therefore necessarily theoretical, based on their individual mechanisms of action and general pharmacological principles.

Both compounds are proposed to influence metabolic pathways, albeit through distinct mechanisms. Retatrutide acts via cell-surface incretin and glucagon receptors, whilst 5-Amino-1MQ works intracellularly by modulating enzyme activity and NAD+ metabolism. In theory, combining agents that both reduce adiposity and improve insulin sensitivity could produce additive or synergistic metabolic effects — but this is entirely speculative and unproven in humans.

Of greater concern are potential risks from combination use:

• Hypoglycaemia risk: Retatrutide enhances insulin secretion in a glucose-dependent manner, which carries a low intrinsic hypoglycaemia risk when used alone. However, if 5-Amino-1MQ also improves insulin sensitivity (as suggested in animal models), combined use — particularly alongside insulin or sulfonylureas — could theoretically increase the risk of low blood sugar to a clinically significant degree.

• Cardiovascular effects: Glucagon receptor agonism (via retatrutide) and GLP-1 receptor agonism have been associated with modest increases in heart rate as a class effect.^[3][2] The cardiovascular impact of 5-Amino-1MQ in humans is entirely unknown.

• Metabolic unpredictability: Simultaneously altering multiple metabolic pathways — incretin signalling, glucagon activity, and NAD+ metabolism — without clinical oversight introduces unpredictable physiological consequences.

• Compounding of unknown risks: Combining two compounds with incomplete human safety data multiplies the uncertainty considerably.

Combined use of retatrutide and 5-Amino-1MQ should not occur outside the context of an ethically approved clinical trial. Online communities promoting these compounds together lack medical or scientific oversight, and anecdotal reports should not be treated as evidence of safety or efficacy.

Speaking to a Healthcare Professional Before Use

UK patients should consult their GP before considering either compound; NICE-approved weight management pathways, including licensed pharmacotherapy and specialist referral, are the appropriate starting point.

Given the significant uncertainties surrounding both retatrutide and 5-Amino-1MQ, consulting a qualified healthcare professional before considering either compound is strongly advisable — and in practical terms, essential for safe decision-making. In the UK, your GP is the appropriate first point of contact for concerns about weight management, metabolic health, or diabetes. They can assess your individual risk profile, review your current medications for potential interactions, and refer you to specialist services where appropriate.

For individuals seeking support with obesity or weight management, NICE-approved pathways exist and should be the starting point. These include:

• Lifestyle interventions (dietary advice, physical activity programmes)

• Licensed pharmacotherapy such as orlistat, or GLP-1 receptor agonists including semaglutide 2.4 mg (Wegovy, NICE TA875) or tirzepatide (Zepbound) where clinically indicated and available

• Referral to tier 3 or tier 4 weight management services, including bariatric surgery assessment where appropriate

Information on NHS weight management services and eligibility for licensed treatments is available via the NHS website and NICE guidance.

If you have already used or are currently using either of these compounds, it is important to disclose this to your GP or pharmacist without delay. Seek urgent medical attention (via NHS 111 or 999 in an emergency) if you experience severe or persistent abdominal pain, persistent vomiting, signs of dehydration (such as dizziness, reduced urination, or extreme thirst), or symptoms suggestive of low blood sugar (such as shakiness, sweating, or confusion). There is no official link between these compounds and specific adverse event reports in the UK at this time, but the absence of reported harm does not confirm safety.

Any suspected side effects from these or any other medicines or research chemicals should be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk.

Healthcare professionals should be aware that patients may present having sourced these compounds online. A non-judgemental, evidence-informed approach to these conversations will support better patient outcomes. Signposting patients to MHRA guidance on unlicensed medicines and the risks of online purchasing is a practical and important step in safeguarding patient welfare.

Frequently Asked Questions